Reactive arthritis: update 2018

García-Kutzbach, Abraham; Chacón-Súchite, J.; García-Ferrer, H.; Iraheta, Isa

doi:10.1007/s10067-018-4022-5

Cited by 69 publications

(69 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…But, Townes et al have stated that relative risk RR is higher for women (RR 1.5 vs. males) and adults (RR 2.5 vs. children) [9]. However, when it comes to genitourinary infections, the risk is higher for men than women with 9:1 ratio [1]. Another study has shown that females are more exposed than male [10].…”

Section: Is the Epidemiology Of Rea Changing?mentioning

confidence: 99%

See 1 more Smart Citation

Reactive Arthritis: Update

Bentaleb

Abdelghani

Rostom

et al. 2020

Curr Clin Micro Rpt

View full text Add to dashboard Cite

Purpose of Review The aim of this paper is to provide an overview about reactive arthritis, with an update regarding pathophysiology and therapeutic approach of the disease, outlining the clinical features and diagnostic approach, based on recent literature review. Recent Findings Reactive arthritis is considered to be part of the spectrum of the spondyloarthritis. Its epidemiology is changing worldwide due to several reasons, among them are as follows: different diagnosis approach and clinical presentations, different grades of infection, microbiome changes, etc. The understanding of pathophysiological models is challenging, but recent studies contribute to elucidate the major factors involved in the development of the disease. The management of ReA depends on the triggering agent and the phase of disease, whether it is acute or chronic. Summary The association between the microbiome changes and spondyloarthropathies (ReA) is becoming increasingly evident. The results regarding the biologic treatment on refectory ReA are promising.

show abstract

Section: Is the Epidemiology Of Rea Changing?mentioning

confidence: 99%

“…In ReA genitourinary transmission, Chlamydia trachomatis (Ct) is the most common cause followed by Ureaplasma urealyticum and other less common germs [1].…”

Section: What Are the Pathophysiologic Model Advances?mentioning

confidence: 99%

Reactive Arthritis: Update

Bentaleb

Abdelghani

Rostom

et al. 2020

Curr Clin Micro Rpt

View full text Add to dashboard Cite

show abstract

“…30 These perturbations are highly dependent on host genetic background. 31 In humans, the most obvious examples of the gut-joint connection are reactive arthritis, described in 1916 by Noël Fiessinger and Emile Leroy, 32 which results after infection by enteropathogenic (and uropathogenic) bacteria, 33 and enteropathic arthritis, described in 1929 by J Arnold Bargen, 34 which is a sequala of inflammatory bowel disease (IBD) and can parallel colitis exacerbations (figure 1). 35 Another example is ankylosing spondylitis, where terminal ileal biopsies demonstrate distinct microbial signatures driven by several core families of bacteria.…”

Section: What Is Known About the Microbiome In Autoimmune Diseasesmentioning

confidence: 99%

The microbiome in rheumatology: Where are we and where should we go?

2020

View full text Add to dashboard Cite

From birth, humans coexist and coevolve with trillions of micro-organisms inhabiting most body surfaces and cavities, referred to as the human microbiome. Advances in sequencing technologies and computational methods have propelled the exploration of the microbiome’s contribution to human health and disease, spearheaded by massive efforts such as the Human Microbiome Project and the Europe-based MetaHit Consortium. Yet, despite the accumulated body of literature and a growing awareness among patients, microbiome research in rheumatology has not had a key impact on clinical practice. Herein, we describe some of the landmark microbiome studies in autoimmunity and rheumatology, the challenges and opportunities of microbiome research and how to navigate them, advances in related fields that have overcome these pitfalls, and future directions of harnessing the microbiome for diagnostic and therapeutic purposes.

show abstract

“…Since IL-17 has been found to play an important role in the pathogenesis of spondyloarthropathy [53], it has been shown that IL-17a monoclonal antibody is effective in the treatment of ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis without serious adverse events [54][55][56]. At present, there are only three IL-17a monoclonal antibodies on the market: secukinumab, ixekizumab and brodalumab.…”

Section: Interleukin-17a Monoclonal Antibodymentioning

confidence: 99%

Treatment of reactive arthritis with biological agents: a review

Zeng¹,

Luo²,

Zhang³

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

The pathogenesis of reactive arthritis (ReA) has not been fully elucidated. In recent years, many researchers have confirmed that multiple cytokines are involved in the occurrence and development of ReA. Although ReA is self-limiting, it is still incurable for some patients who have no or a weak response to traditional drugs, such as non-steroidal anti-inflammatory agents, glucocorticoids and immunosuppressive agents. This is called refractory reactive arthritis. Currently, there is insufficient evidences for the treatment of refractory ReA with biological agents, though biological agents against cytokines have been developed over the past few years. This review summarizes the current development of clinical treatments of ReA with biological agents, which provides future investigations on refractory ReA with more evidence and references.

show abstract

Reactive arthritis: update 2018

Cited by 69 publications

References 38 publications

Reactive Arthritis: Update

Reactive Arthritis: Update

The microbiome in rheumatology: Where are we and where should we go?

Treatment of reactive arthritis with biological agents: a review

Contact Info

Product

Resources

About